ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "immunology"

  • Abstract Number: 111 • 2023 Pediatric Rheumatology Symposium

    Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center

    Omar Mostafa, Sharon Bout-Tabaku, Buthaina Al-Adba, Ahmad Kaddourah, Abubakr Imam, Ibrahim Shatat and Mohammed Yousuf Karim, Sidra Medicine, Ar-Rayyan, Qatar

    Background/Purpose: Hypogammaglobulinemia is an under-recognized complication of B-cell targeted therapies (BCTT) in both autoimmune diseases (AID) and malignancy. Hypogammaglobulinemia may be transient or persistent, and…
  • Abstract Number: L04 • ACR Convergence 2022

    Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Soumyaroop Bhattacharya3, Jeffrey Fox4, Ernest Meyer5, Brian Isett5, Riyue Bao6, Tullia Bruno6 and Christopher Ritchlin7, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, 4CMSR, University of Rochester Medical Center, Rochester, NY, 5UPMC Hillman Cancer Center, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA, 7University of Rochester Medical Center, Rochester, NY

    Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
  • Abstract Number: L03 • ACR Convergence 2022

    A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

    Jay Tuttle1, Edit Drescher2, Jesus Abraham Simón-Campos3, Paul Emery4, Maria Greenwald5, Alan Kivitz6, Hyungmin Rha1, Pia Yachi1, Christina Kiley1 and Ajay Nirula7, 1Eli Lilly and Company, Indianapolis, IN, 2Csolnoky Ferenc Hospital, Veszprém, Hungary, 3Köhler & Milstein Research/Hospital Agustín O'Horán, Merida, Yucatan, Mexico, 4University of Leeds, Leeds, United Kingdom, 5Desert Medical Advances, Palm Desert, CA, 6Altoona Center for Clinical Research, Duncansville, PA, 7Eli Lilly, San Diego, CA

    Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1,…
  • Abstract Number: L10 • ACR Convergence 2022

    Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)

    Sarah Julien1, Emma Briand1, Bas van der Woning2, Leentje de ceuninck3, Rachid zoubari1, olivier benveniste4, laurent drouot1 and olivier boyer5, 1INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, 2argenx, Boston, MA, 3argenx, Ghent, Belgium, 4AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, 5INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France

    Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…
  • Abstract Number: 0040 • ACR Convergence 2022

    Plasma Proteomic Signatures in Juvenile Dermatomyositis Highlight Novel Proteins and a Protein Module That Associate with Skin and Global Disease Activity

    Marianne Kerski1, Celine Berthier1, Alex Tsoi1, Sarah Vandenbergen1, Madison McClune1, Corey Powell1, J. Michelle Kahlenberg1 and Jessica Turnier2, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Saline, MI

    Background/Purpose: Juvenile dermatomyositis (JDM) patients display heterogenous disease phenotypes and treatment response patterns. Our study used a multiplexed proteomics assay for measurement of 3072 proteins…
  • Abstract Number: 0608 • ACR Convergence 2022

    Wnt Pathway Regulators R-spondin 3 and Dickkopf-related Protein 3 Demarcate a Transcriptional Gradient That Drives Synovial Fibroblast Inflammatory Pathology in Rheumatoid Arthritis

    Alisa Mueller1, Angela Zou2, SABA NAYAR3, Emily Taylor3, Triin Major3, David H Gardner3, Gerald FM Watts1, Adam Croft3, Roche Fibroblast Network Consortium4, Andrew Filer3, Christopher Buckley5, Kevin Wei6, ilya Korsunsky1, Soumya Raychaudhuri1 and Michael Brenner7, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3University of Birmingham, Birmingham, United Kingdom, 4Roche, Basel, Switzerland, 5University of Oxford, Oxford, United Kingdom, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Synovial fibroblasts are key players in rheumatoid arthritis (RA) where they secrete inflammatory cytokines and directly instigate cartilage and bone destruction. However, most treatments…
  • Abstract Number: 0760 • ACR Convergence 2022

    Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors

    Alexandra Ladouceur1, Marina Amaral De Avila Machado2, Marie Hudson1, Cristiano Moura3 and Sasha Bernatsky3, 1McGill University, Montréal, QC, Canada, 2Research Institute of McGill University Health Center, Montréal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: Since patients with pre-existing autoimmune conditions are commonly excluded from clinical trials with immune checkpoint inhibitors (ICI), we aimed to describe the characteristics of…
  • Abstract Number: 1171 • ACR Convergence 2022

    Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease

    Phan Saligrama1, Erin Wilfong2, Elise Rizzi3, Leslie Crofford2 and Peggy Kendall1, 1Washington University, Saint Louis, MO, 2Vanderbilt University Medical Center, Nashville, TN, 3Pennsylvania State University, Hershey, PA

    Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease…
  • Abstract Number: 1705 • ACR Convergence 2022

    Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis

    Joseph Rouse1, Amanda Wahhab1, Rebecca Danner1, Brandon Jutras2, Adam Edelstein3, Klemen Strle4 and Robert Lochhead5, 1Medical College of Wisconsin, Milwaukee, WI, 2Virginia Tech, Blacksburg, VA, 3Northwestern Medicine, Chicago, IL, 4Wadsworth Center, Albany, NY, 5Medical College of Wisconsin, Germantown, WI

    Background/Purpose: Lyme arthritis (LA), caused by infection with Borrelia burgdorferi (Bb), is characterized by proliferative synovitis accompanied by dysregulated autoimmune Th1 responses. Fibroblast-like synoviocytes (FLS)…
  • Abstract Number: 1936 • ACR Convergence 2022

    A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype

    Sara Alehashemi1, Adriana Almeida de Jesus2, Jonas Johannes Papendorf3, Farzana Bhuyan4, Kat Uss5, Anvitha Metpally6, Bin Lin7, Sophia Park8, Thais C.L. Moura9, Renata R Dias9, Mayra B. Dorna9, Katia Kozu9, Adriana Sallum9, Lucia M. A. Campos9, Gijs Santen10, Jesper Kers10, Onno Teng11, Karin Palmblad12, Tom Huizinga10, Frédéric Ebstein13, Elke Krüger13 and Raphaela Goldbach-Mansky14, 1NIH/NIAID/TADS, Clarksville, MD, 2NIAID, NIH, Silver Spring, MD, 3Institut für Medizinische Biochemie und Molekularbiologie, Universitätsmedizin Greifswald, Greifswald, Germany, 4National Institutes of Health, Bethesda, MD, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6NIAID, NIH, Bethesda, MD, 7NIH, Bethesda, MD, 8NIAID, Bethesda, MD, 9Children's Hospital of the University of São Paulo, São Paulo, Brazil, 10Leiden University Medical Center, Leiden, Netherlands, 11Leiden University Medical Center, Leiderdorp, Netherlands, 12Karolinska University Hospital, Stockholm, Sweden, 13Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, 14NIH/NIAID, Potomac, MD

    Background/Purpose: Homozygote (HM)/compound heterozygote (CH) and digenic (DG) mutations in proteasome subunits cause the autoinflammatory syndrome CANDLE, or proteasome-associated autoinflammatory syndrome (PRAAS). Inflammation is mediated…
  • Abstract Number: 0047 • ACR Convergence 2022

    Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis

    Thomas Hoyler, Jeremy Scherer, Maxime Bulle, Conrad Wyss, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland

    Background/Purpose: Targeting the sphingosine-1-phosphate (S1P) pathway has become an attractive target for therapeutic intervention in autoimmune diseases due to its selective impact on the migration…
  • Abstract Number: 0615 • ACR Convergence 2022

    Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis

    Qi Cheng, Mo chen, Mengdan Liu, Xin chen, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…
  • Abstract Number: 0769 • ACR Convergence 2022

    Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial

    Daniela Sieghart1, Daniel Mrak1, Elisabeth Simader1, Selma Tobudic2, Helga Radner1, Peter Mandl3, Lisa Göschl1, Maximilian Koblischke4, Nikolaus Hommer5, Lukas Hartl6, Philipp Hofer7, Felix Kartnig1, Thomas Hummel1, Andreas Kerschbaumer3, Thomas Deimel3, Antonia Puchner1, Renate Thalhammer8, Andreas Zuckermann9, Karin Stiasny4, Thomas Perkmann8, Helmuth Haslacher8, Markus Zeitlinger5, Ursula Wiedermann10, Judith Aberle4, Daniel Aletaha11, Leonhard Heinz1 and Michael Bonelli1, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, 3Medical University of Vienna, Vienna, Austria, 4Center for Virology, Medical University of Vienna, Vienna, Austria, 5Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, 6Division of Gastroenterology, Medical University of Vienna, Vienna, Austria, 7Department of Pathology, Medical University of Vienna, Vienna, Austria, 8Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, 9Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 10Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology & Immunology, Medical University Vienna, Vienna, Austria, 11Medical University Vienna, Wien, Austria

    Background/Purpose: Patients under immunosuppressive therapy have a high risk for severe COVID-19 disease courses. However, efficacy of vaccination and therefore the right vaccination strategy remains…
  • Abstract Number: 1174 • ACR Convergence 2022

    Cellular Immunotherapy for Systemic Sclerosis

    Chanhyuk Park1, Rajan Bhandari2, Jason Gunn3, Timothy Sullivan2, Gretel Torres2, Joana Murad3, Michael Whitfield4 and Patricia Pioli2, 1Geisel School of Medicine at Dartmouth, West Lebanon, NH, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Celdara Medical, Lebanon, 4Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Pro-fibrotic macrophages (MØs) are implicated in the pathogenesis of systemic sclerosis (SSc). In prior work, we and others have shown that MØs derived from…
  • Abstract Number: 1717 • ACR Convergence 2022

    Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli

    Afroditi Boulougoura1, Hao Li1, Rhea Bhargava1, Wenliang Pan1, Abhigyan Satyam1, Isaac Stillman2 and George Tsokos1, 1Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Interleukin 23 (IL-23) is involved in the pathogenesis of systemic lupus erythematosus (SLE). IL-23 is elevated in the sera of patients with active SLE…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences